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The purpose of this case is to explore the recent and eye-opening
revelations of pervasive confiicts of interest throughout the United States
medical industry, and to provide a framework within which the revelations
can be examined and better understood. These revelations should provide
rich, pedagogical fodder to professors of legal and ethical responsibilities of
business executives, and enable those professors to demonstrate clearly the
nature of confiicts of interest and the significant impact they play in the
executives' ability to meet their obligations to stakeholders.
Conflicts of interest arise whenever executives have a private interest in
the outcome of the task or responsibility they carry out on behalf of their
employers. As a company employee, the executive owes his employer the
duty to act solely for the benefit of his or her employer and not in the interest
of the employee or third party; the employee's loyalty must be undivided.'
As an officer of the company, the executive is an agent of the corporation,
and owes the corporation the same fiduciary duties as those imposed on
employees, including the duty to act solely for the benefit of the corporation.^
Whenever a confiict of interest exists, the executive cannot be said to act
solely for the benefit of the employer. The conflict of interest may cause the
executive to engage in a course of action that is not in the best interest of the
company, or to fail to exercise independent judgment on behalf of the
company, thereby breaching the duty of loyalty the executive owes to his
J.D., Professor of Management, Rohrer College of Business, Rowan University, Glassboro,
New Jersey.
Ph.D., Associate Professor of Marketing and Chairperson, Department of Marketing and
Business Information Systems, Rohrer College of Business, Rowan University, Glassboro,
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*** J.D., Professor of Business Administration and Chairperson, Business Administration and
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' FRANK B . CROSS AND ROGER LEROY MILLER, THE LEGAL ENVIRONMENT OF BUSINESS: TEXT
& CASES 486 (7th ed. 2009).
^ Id. at 455.
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employer. For example, a business executive has a conflict of interest if she
owns stock in a company submitting a bid to the executive's employer: the
executive may be tempted to enhance the value of stock she owns in the
bidding company by approving its bid. Likewise, a business executive who
enters into a contract on behalf of his employer to purchase consulting
services from company owned by his daughter has conflicting interests: the
executive may be more interested in benefiting his daughter than in obtaining
the best terms for the employer. Similarly, a business executive who serves
as a consultant to a third party and negotiates a lease or purchase agreement
between the third party and his employer cannot be said to be acting solely in
the interest of his employee.
Unfortunately, the importance of conflicts of interest in examining the
legal and ethical obligations of executives is ft^equently understated, because
the explanation normally accorded them is couched in singular instances,
such as the three examples cited above, all of which involve a single contract
and none of which posed a significant impact beyond the immediate parties
to the contracts in question. Such is not the case, however, in the conflicts of
interest pervading the medical industry. Indeed, because these conflicts of
interest threaten the public interest in safety and effectiveness of medical
treatments and devices, they elevate the importance of addressing conflicts of
interest in legal and ethical responsibility courses. Further, the professor
teaching in these areas occupies the unique position of addressing ethical
issues residing in her own or similar academic institutions, rather than
critiquing ethical issues in outside business organizations. In effect, the
professor is charged with putting his own house in order, rather than
critiquing the activities of unrelated parties.
This case examines: (1) the extent and purpose of payments routinely
made by the medical industry to physicians employed by academic
organizations or engaged in private practice; (2) the failure of physicians to
comply with regulations requiring them to disclose their conflicting financial
interests; (3) the inability of the medical and research system to effect
compliance with disclosure requirements; (4) forces inherent in the medical
research system which have increased the incidence of conflict of interest,
namely vertical integration of the pharmaceutical industry, the 1980 Bayh-
Dole Act, and the accelerating need of the medical industry to conduct
human experiments; (5) changes in medical research spawned by the
increased dependence of drug and medical device companies on private
industry medical research, namely industry contributions to physicians'
nonprofit foundations, ghost written medical research, and the rise of the
celebrity medical expert; (6) responses of medical institutions and academic
organizations to the conflict of interest revelations; and (7) the three major
^ MANUEL G. VELASQUEZ, BUSINESS ETHICS: CONCEPTS AND CASES 430-31 (4th ed. 1998).
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solutions proposed to combat conflicts of interest in the medical research
industry: mandatory disclosure of financial conflicts, instituting independent,
federal testing of medical research results, and the AMA conflict of interest
policy proposal.
II . M E D I C A L INDUSTRY PAYMENTS T O PHYSICIANS
The relationships between physicians and medical related companies in
the United States, generally acknowledged to be cozy given their mutual
interest in patient care, also tum out to be quite pervasive and lucrative. A
survey of U.S. doctors undertaken by Harvard University in 2003 and 2004,
in which nearly half of the 3,167 practicing anesthesiologists, cardiologists,
family practitioners, general surgeons, intemists and pediatricians responded,
demonstrates that one-quarter of the respondents acknowledge receiving
payments from medical industry companies.'* Similarly, a study published in
the New England Journal of Medicine revealed that 80% ofthe responding
doctors accepted free food or dmg samples, one-third admitted being
reimbursed for travel expenses to attend professional meetings or continuing
medical education, and 28% reported they were paid for consulting, giving
lectures, or signing up patients for clinical trials.^
Physicians serving as department heads in medical schools and teaching
hospitals are also fmancially tied to the medical industry. In a survey
published in the Journal ofthe American Medical Association, two-thirds of
department heads acknowledge they have financial or other ties to the
" Survey finds doctor links with industry, UPI (Apr. 26, 2007),
http://it.moldova.org/news/survey-fmds-doctor-links-with-industry-44482-eng.htmL
' Christopher Lee, Drugmakers, Doctors Get Cozier: Gifts Continue, Contacts Increase





spite+Guidelines; Robert Cohen, Doctors routinely receive perks jrom pharmaceutical
industry, STAR-LEDGER, Apr. 26, 2007, at 79.
Family practitioners reported the highest number of meetings with drug company
representatives (sixteen per month), followed by intemists (nine per month), and cardiologists
(ten per month). Doctors in group practices were three times as likely to receive gifts and
nearly four times more likely to be paid for professional services than physicians practicing in
hospitals. Eric G. Campbell et al., A National Survey of Physicians - Industry Relationships,
NEW ENG. J. MED. (Apr. 26, 2007), http://content.nejm.org/cgi/content/full/356/17/1742. The
drug industry has collectively decided to terminate the small gifts (e.g., pens, notepads,
staplers, clocks, calculators, stethoscope lights, and other trinkets and knickknacks)
pharmaceutical companies give to doctors effective January 1, 2009. See Alan Bavley, Drug
industry, government, schools tackle conflicts, CHATTANOOGA TIMES FREE PRESS, Oct. 12,
2008, at A8.
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industry (e.g., received research equipment or money to support residency
and fellowship training, continuing medical education and research seminars
from companies), 27% report that they worked as paid consultants, 27%
report they served on companies' scientific advisory boards, 9% report they
founded companies, and 7% report they served as company officers or
executives.*
These types of financial relationships constitute conflicts of interest,
which "occur when physicians have motives or are in situations for which
reasonable observers could conclude that the moral requirements of the
physician's roles are or will be compromised," and which pose a "serious
threat . . . for professionalism and for the trust that patients have in
physicians."'
ni . FAILURE TO REPORT SIGNIFICANT CONSULTING COMPENSATION
AND EQUITY HOLDINGS
While the above noted survey results standing alone do not indict the
relationships between doctors and the medical industry, extensive
information unearthed by Senator Charles E. Grassley (R. Iowa), ranking
member of the United States Senate Committee on Finance, reveals
multifaceted relationships between U.S. physicians and the medical industry,
which have attracted significant attention and raise ethical concerns. Four
recent revelations show that leading academic researchers at major
universities have received, but failed to fully report, significant consulting
fees fi'om the medical industry.
First, the Senate Finance Committee reported that Psychiatry Professor
Alan Schatzberg, a renowned and highly respected member of the Stanford
Universify School of Medicine and President of the American Psychiatric
Association, failed to report a $22,000 payment from Johnson & Johnson for
consulting services, ownership of stock worth $6 million in Corcept
* Katherine Mangan, Medical Schools See Many Ties to Industry, CHRON. HIGHER EDUC. (Oct.
26, 2007), at http://chronicle.com/weekly/v54/i09/09a03103.htm. See Charles Huckabee,
Another Academic Physician's Tied to Industry Come Under Senator's Scrutiny, CHRON.
HIGHER EDUC. (July 28, 2009), at http://chronicle.com/article/Another-Academic-
Physicians/47484/7utm_source=at&utm_medium=en. (Medtronic, a medical device company,
made $1.14 million in payments to a University of Minnesota medical professor who receive
research ftinds from the Pentagon to undertake a study involving one of the company's
products and failed to disclose his consulting relationship with the company when he appeared
before a Senate panel to urge the Defense Department to support research into combat relate
injuries.).
' Troyen A. Brennan, MD, MPH, et. al.. Health Industry Practices That Create Conflicts of
Interest: A Policy Proposal for Academic Medical Centers, J. AM. MED. ASS'N, Jan. 25, 2006,
at 430.
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Therapeutics which he cofounded in 1998 and which recently developed the
drug Mifepristone (RU-486) for the treatment of depression, and $109,179
profits from sales of Corcept stock in 2005.^ As a consequence of these
disclosures. Professor Schatzberg was forced to resign as principal
investigator on his grant from the National Institutes of Health (NIH) to
investigate the biology of psychotic depression and to determine the
effectiveness of Mifepristone as an antidepressant.' The results of that
research are clearly capable of affecting the value of his Corcept stock.
Second, Senator Grassley accused Professor Jeffrey C. Wang, chief of
UCLA's Orthopedic Spine Service, of violating university procedures by
failing to inform UCLA that he received payments in the approximate
amount of $459,000 during the period 2004 to 2007 from Medtronic,
Johnson & Johnson, and FzioMed for royalties, consulting fees, and speaking
fees.'" In response to these accusations, UCLA removed Dr. Wang fi-om his
position as chief of the spine-surgery center."
Third, Senator Grassley accused Harvard University Medical School
Psychiatrist Joseph Biederman of failing to report consulting income
received from drug companies in the amount of $1.6 million during the
period 2000 to 2007.'^ Dr. Biedermann, a widely recognized expert on the
use of antipsychotic drugs in children, whose studies are often financed by
the drug makers and contributed to a 40-fold increase in the diagnosis of
pédiatrie bipolar disorder,'^ persuaded Johnson & Johnson, the manufacturer
Ryan Mac, Iowa senator targets Stanford Prof for conflict of interest, STANFORD DAILY (July
10, 2008), http://www.cbsnews.com/stories/2008/07/10/politics/uwire/main4250153.shtml;
Arlene Weintraub, Drugmakers and College Labs: Too Cozy, Bus. WEEK (June 26, 2008),
http://www.businessweek.com/print/technology/content/jun2008/tc20080626_630542.htm;
and Kent Garber, Committee Questions a Top Psychiatrist, U.S. NEWS & WORLD REPORT
(June 26, 2008), http://politics.usnews.com/news/national/articles/2008/06/26/committee-
questions-a-top-psychiatrist.html.
Maria Jose Vinas, Stanford Researcher, Accused of Conflicts, Steps Down as NIH Principal
Investigator, CHRON. OF HIGHER EDUC. (Aug. 1, 2008), http://chronicle.com/article/Stanford-
Researcher-Accuse/41395/.
'" Paul Basken, UCLA Surgeon Accused of Hiding Medical Company's Payments, CHRON. OF
FIiGHER EDUC. (May 28, 2009), http://chronicle.com/article/UCLA-Surgeon-Accused-of-
Hid/47658/.
' ' Paul Basken, UCLA Investigates Corporate Payments to a Surgeon at Its Medical School,"
CHRON. OF HIGHER EDUC. (July 21, 2009), http://chronicle.com/article/UCLA-Investigates-
Corporate/47423.
" Harvard Psychiatrists Underreported Earnings from Drug Companies, Investigators Say,
CHRON. OF HIGHER EDUC. (June 8, 2008) http://chronicle.com/article/Harvard-Psychiatrists-
Under/41117/; KAISER DAILY HEALTH POLICY REPORT, THE HENRY J. KAISER FAMILY
FOUNDATION (June 9. 2008),
hnp://www.kaisemetwork.org/daily_reports/rep_index.cfin?DR_ID=52614.
" Gardiner Harris and Benedict Carey, Researchers Fail to Reveal Full Drug Pay, N.Y. TIMES
(June 8, 2008),
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of Risperdal, to establish and fund the Johnson & Johnson Center for the
Study of Pédiatrie Psychopathology at Boston's Massachusetts General
Hospital to conduct clinical trials to determine appropriate use and dosing of
Risperdal in children.'" Dr. Biedermann and his colleagues published the
results ofthat research in many articles favorable to the drug,'^ even though
those clinical trials were apparently conducted contrary to restrictions
imposed by Harvard University and Massachusetts General prohibiting
researchers from conducting clinical trials if they receive payments of more
than $20,000 from a drug maker.'*
Finally, Senator Grassley accused Charles B. Nemeroff, a prominent
Emory University psychiatrist, of failing to report at least one third of the
$2.8 million in consulting fees he received from GlaxoSmithKline between
2000 and 2007, while he was the principal investigator on a $3.9 million
grant from NIH to study five Glaxo drugs for treatment of depression."
While Emory University regulations prohibit the acceptance of more than
$10,000 per year from any one company. Dr. Nemeroff exceeded that
threshold each year between 2003 and 2006 but lied about it to Emory.'^ Dr.
Nemeroff resigned as the principal researcher of the NTH grant on October
24, 2008, pending an investigation into his relationship with the drug
company." Upon completion of the investigation, Emory University
http://www.nytimes.com/2008/06/08/us/08conflict.html?_r=l&scp=l&sq=Researchers%20Fa
il%20to%20Reveal%20Full%20Drug%20Pay&st=cse.
'"* David Armstrong and Alicia Mundy, J&J Emails Raise Issues of Risperdal Promotion,
WALL ST. J. (Nov. 25, 2008),
http://online.wsj.com/article/SB122755237429253763.html7KE YWORDS=JJ+Emails+Raise
+Issues+of+Risperdal+Promotion; Gardiner Harris, Research Center Tied to Drug Company,
N.Y. TIMES (NOV. 25, 2008),
http://www.nytimes.eom/2008/l l/25/health/25psych.html?scp=l&sq=Research%20Center%2
0Tied%20to%20Drug%20Company&st=cse.
'̂  Armstrong, supra note 14.
" Id. See For Harvard Psychiatrist, Professorliness Is Next to Godliness, CHRON. OF HIGHER
EDUC. (Mar. 20, 2009), http://chronicle.com/article/For-Harvard-Psychiatrist-P/42600/ (In
advance of his research. Dr. Biederman promised Johnson & Johnson that the proposed drug
trial "will clarify the competitive advantages of risperidone vs. other neuroleptics.").
" Denise Gellene and Thomas H. Maugh II, Doctor Accused in Congress ' Probe, Los






" Emory U. Psychiatrist Failed to Report Income from Drug Makers, CHRON. OF HIGHER
EDUC. (Oct. 4, 2008), http://chronicle.com/article/Emory-U-Psychiatrist-Faile/41743/.
" Chrissie Cole, NIH Suspends Emory University Grant, THE INJURY BOARD NATIONAL NEWS
DESK (Oct. 14, 2008), http://news.injuryboard.com/nih-suspends-emory-university-grant-
.aspx?googleid=249420.
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announced that Dr. Nemeroff relinquished his post as Department Chair, a
position he held for 17 years, that it would not submit a NIH or other
sponsored grant or contract requests listing Dr. Nemeroff as an investigator
or in any other role for a period of at least two years, and that Dr. Nemeroff
must submit any compensation requests for speaking engagements to the
dean's office for review.^"
While those actions penalized Emory University, they did not deter Dr.
Nemeroff. NIH continued his eligibility to serve on NIH advisory panels
providing recommendations on who received grant funding.^' One year later.
Dr. Nemeroff accepted the position of professor and chairman of the
department of psychiatry and behavioral sciences at the University of
Miami.^^ Dr. Nemeroff landed the job shortly after Thomas R. Insel, Director
of the National Institute of Mental Health, responding to the inquiry of the
dean of the University of Miami's medical school, confirmed that Dr.
Nemeroff was NLH grant eligible and could begin applying for NIH grants as
soon as he arrived on campus.^^ Dr. Insel also gave the dean a positive
recommendation of Dr. Nemeroff in an ensuing telephone conversation, NIH
rules prohibiting a formal, written recommendation.^" Dr. Insel's assistance
reportedly was pay-back for earlier help given to him by Dr. Nemeroff.
When Dr. Insel faced nonrenewal of his research position at NIH in 1994,
Dr. Nemeroff hired him as professor of psychiatry and research director, and
later lobbied in favor of Dr. Insel's appointment as Director of NTMH in
2002."
^̂  Emory U. Scientist Penalized for Hidden Payments From Drug Company, CHRON. OF
HIGHER EDUC. (Dec. 29, 2008), http://chronicle.com/article/Emory-U-Scientist-
Penalize/42166/. Emory University publicly disclosed another psychiatrist's conflict of
interest, when its medical school dean issued a letter of reprimand to Zachary N. Stowe, a
professor of psychiatry, for failure to reveal he was paid by GlaxoSmithKline, a manufacturer
of antidepressants, at the same time Dr. Stowe conducted a federally ñnanced study of the use
of the drugs in pregnant women. Paul Basken, Emory U. Penalizes Another Psychiatrist With
Hidden Financial Conflicts of Interest, CHRON. OF HIGHER EDUC. (June 10, 2009),
http://chronicle.com/article/Emory-U-Penalizes-Another-/47727/.
^ ' Paul Basken, NIH Director Says New Rules on Conflicts May Need to Be Toughened
Further, CHRON. OF HIGHER EDUC. (June 11, 2010), http://chronicle.com/article/NIH-Director-
Says-New-Rules-on/65905/?sid=at&utm_source=at&utm_medium=en.
^̂  Paul Baskin, As He Worked to Strengthen Ethics Rules, MIMH Director Aided a Leading
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rv. IMPOTENCE OF NIH, FDA, AND UNIVERSITIES TO UNCOVER
CONFLICTS OF INTEREST
The four cases discussed above underscore the significance of the
confiicts of interest uncovered by Senator Grassley and the impotence of
NIH and the physicians' academic institutions to prevent them. While federal
regulations require that researchers receiving NIH grants remain free of
financial conflicts of interest (defined as receiving more than $10,000 per
year or owning more than 5% of an entity that might bias their work), NIH
relies on the academic institutions to gather financial information from grant
investigators and to manage or eliminate conflicts of interest, but does not
require universities to provide information about the confiicts or how they
are resolved.^* Indeed, a report ofthe inspector general ofthe Department of
Health and Human Services concedes NIH does not know the number or
nature of confiicts of interest and does not track how universities and other
institutions resolved them.^' Perhaps prompted by the steady stream of
financial confiicts of interest in scientific research, NIH recently published a
notice in the Federal Register announcing it would initiate formal mle
making procedures to control how institutions better guarantee their research
scientists are not biased by outside company payment.^^
The FDA may be faring no better than NIH. The Office of Inspector
General of the U.S. Department of Health and Human Services audited the
financial disclosures made by researchers in "all 118 marketing applications
approved by the FDA in the 2007 fiscal year," determined that "[o]nly 1
" Jeffrey Brainard, NIH Turns Blind Eye to Academics ' Financial Conflicts, Audit Says,
CHRON. OF HIGHER EDUC. (Feb. 1, 2008), http://chronicle.com/weekly/v54/i21/21a00801.htm;
Richard Monastersky, Hidden Payments to University Researchers Draw New Fire, CHRON.
OF HIGHER EDUC. (Oct. 31, 2008), http://chronicle.com/weekly/v55/ilO/10a01301.htm.;
Jeffrey Brainard, Senator Grassley Pressures Universities on Conflicts of Interest, CHRON. OF
HIGHER EDUC. (Aug. 8, 2008), http://chronicle.com/weekly/v54/i48/48a01201.htm.
" Gardiner Harris, Researchers Go Unchecked, Report Says, N.Y. TIMES (Jan. 19, 2008),
http://www.nytimes.com/2008/01/19/us/19conflict.html?_r=l&scp=l&sq=Researchers%20Go
%20Unchecked,%20Report%20Says&st=cse.
" Paul Basken, NIH Plans New Rules to Police Researchers ' Financial Conflicts of Interest,
CHRON. OF HIGHER EDUC. (May 11, 2009), http://chronicle.com/news/article/6456/nih-plans-
new-rules-to-police-researchers-financial-conflicts-of-
interest?utm_source=at&utm_medium=en. In response to NIH's request for public comment,
two academic organizations, the Association of American Universities and the Association of
American Medical Colleges, submitted a joint letter urging NIH to increase its oversight over
research conflicts of interest and recommending that all research investigators report all
fmancial conflicts of interest to their academic institutions related directly or indirectly to their
research regardless ofthe amount of money involved. Katherine Mangan, 2 Academic
Associations Urge the NIH to Increase Oversight of Research Conflicts, CHRON. OF HIGHER
EDUC. (June 11,2009),
http://chronicle.com/daily.'2009/06/19810n.htm?utm_source=at&utm_medium=en.
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percent of clinical investigators disclosed a financial interest in the products
they studied," and concluded that "[c]linical investigators may not be
disclosing all fmancial interests."^' In contrast, and as noted above, the
Harvard University survey of U.S. doctors determined that 28% of doctors
were paid for consulting, giving lectures, or signing up patients for clinical
trials, and the AMA survey determined that 27% of medical school
department heads worked as paid consultants.
Further, most universities rely on their professors to report fmancial
information, but lack the wherewithal to verify the information they submit.^"
Only a handful of states (Minnesota, Vermont, Maine, West Virginia, and
California) and the District of Columbia require some level of disclosure of
pharmaceutical company payments to physicians.^' Hence, there is no
database which universities can use to check the disclosures made by
physicians to their academic institutions or which informs the public of the
fees paid by drug companies to physicians for consulting, speeches, and
clinical trials.^^ Moreover, the information submitted by universities to NIH
about conflicts of information is not helpful: two-thirds of the reports failed
to provide basic information describing the confiict and 90% failed to
" Paul Basken, FDA Is Not Doing Enough to Thwart Conflicts of Interest in Research, Audit
Finds, CHRON. OF HIGHER EDUC. (Jan. 12, 2009), http://chronicle.com/news/article/5782/the-
fda-is-not-doing-enough-against-conflicts-of-interest-audit-
finds7utm_source=at&utm_medium=en. The Inspector General's report caused Senator
Grassley to remark: "It looks like the ability of the Food and Drug Administration to track
fmancial ties is just as broken down as that of the National Institutes of Health." See Press
Release, Grassley Comments on FDA Tracking of Clinical Investigators' Financial Ties (Jan.
12, 2009) (http://grassley.senate.gov/news/Article.cfm7customel_dataPageID_l 502= 18741 ).
' Basken, supra note 29.
' ' Gardiner Harris and Janet Roberts, A State's Files Put Doctors ' Ties to Drug Makers on a
Close View, N.Y. TIMES (Mar. 21, 2007),
http://www.nytimes.com/2007/03/21/us/21drug.html7scp=l&sq=A+State%92s+Files+Put+Do
ctors%92+Ties+to+Drug+Makers+on+a+Close+View&st=nyt. The Vermont legislature
recently approved a law requiring the disclosure of fmancial conflicts of interest involving
drug and medical device makers and physicians, nurses, pharmacists, and other health-care
providers. The law also bans industry-sponsored meals and nearly all other gifts to health-care
providers. Katherine Mangan, Vermont Legislature Cracks Down on Drug Company Gifts,
CHRON. OF HIGHER EDUC. (May 19, 2009), http://chronicle.com/news/article/6504/vermont-
Iegislature-cracks-down-on-dnig-company-gifts7utm_source=at&utm_medium=en. A
Massachusetts statute bans all gifts from pharmaceutical and medical device companies to
physicians. David Armstrong, Two States Restrict Firms ' Gifts to Doctors, WALL ST. J. (July
1, 2009), http://online.wsj.com/article/SB124640634767976599.html.
See, e.g., Maura Lemer et al.. Doctors ' ties to drug firms raise concern. STAR TRIBUNE
(Mar. 23, 2007),
http://www.prescriptionproject.org/assets/pdfs/StarTribune%20March%2023.pdf (detailing
the income earned by Minnesota physicians and reported by medical companies to the
Minnesota Pharmacy Board).
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describe how the conflict was resolved.^^ Indeed, a recent survey led by the
Association of American Medical Colleges found that fewer than 40% of
medical schools have policies governing institutional conflicts of interest,^''
and the results of a recent survey of 211 chairmen of institutional review
boards at research-intensive medical institutions in the United States
demonstrate that one-third of the review boards did not require voting
members to disclose any fmancial relationships with outside companies.''^
Further, a recent audit conducted by the inspector general of the Department
of Health and Human Services demonstrated that "[u]niversities involved in
federally sponsored medical research rarely take steps to investigate, reduce,
or eliminate fmancial conflicts of interest among their scientists," that
universities rarely direct the scientists to alter their financial relationships
when confiicts are acknowledged, and that "the NIH does little, if anything,
to police the matter."^*
V. INHERENT FORCES FOMENTING CONFLICTS OF INTEREST
Several forces have coalesced to increase the incidence of conflicts of
interest in the medical industry: the vertical integration of the pharmaceutical
industry, the 1980 Bayh-Dole Act, and the rapidly accelerating need of the
medical industry to conduct human experiments.
A. Vertical Integration of Pharmaceutical Industry
The pharmaceutical industry has become increasingly vertically
integrated, giving drug companies control over the entire chain of
production.^^ Drug companies develop new products, hire university and
private-sector researchers to conduct drug trials, contribute to the design and
pay for the study, and control which study results get published.^^ Drug
" Brainard, supra note 26.
" Monastersky, supra note 26 ("A recent survey let by the Association of American Medical
Colleges found that less than 40 percent of medical schools have policies governing
institutional conflicts of interest, such as might arise when a company provides money directly
to a university or to its senior officials. Over two-thirds of the medical colleges have more-
limited policies governing payments to senior officials, but more than 20 percent of the
institutions did not have even those narrow policies.").
'^ Paul Basken, Campus Medical-Review Boards Oflen Fail to Police Themselves, Survey
Finds, CHRON. OF HIGHER EDUC. (Mar. 26, 2009),
http://chronicle.com/daily/2009/03/14555n.htm?utm_source=at&utm_medium=en.
•'* Paul Basken, Federal Audit Faults Universities Over Researchers ' Financial Conflicts of
Interest, CHRON. OF HIGHER EDUC. (Nov. 19, 2009), http://chronicle.com/article/Federal-
Audit-Faults/49220/?sid=pm&utm_source=pm&utm_medium=en.
" Sheldon Krimsky, A Dose of Reform, STAR LEDGER, Feb. 20, 2005, at 1.
"Id
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companies also market prescription drugs directly to consumers and
physicians,^' support medical journals and conferences through advertising
and contributions, fund physician continuing education'*" and medical
symposia, pay consulting fees to physicians for giving presentations and
serving on committees and boards,'" have fmancial relationships with the
authors of guidelines establishing standards for prescribing medicines, ''̂  and
provide financial incentives to physicians to promote off-label prescriptions
of drugs to provide data justifying the alternative uses of pharmaceutical
products.''^ Using their increased vertical control, as will be discussed more
•" Some legislators have responded to the direct marketing of drugs to consumers by
introducing legislation to ban ads for prescriptions such as Viagra and Levitra in prime time
television on decency grounds and to empower the FDA to prohibit tax deductions for drug
advertisements directed to consumers. Natasha Singer, Lawmakers Seek to Curb Drug
Commercials, N.Y. TIMES (July 27, 2009),
http://vsfww.nytimes.com/2009/07/27/bus iness/media/27drugads.html?_r=l&scp=l&sq=Lawm
akers%20Seek%20to%20Curb%20Dmg%20Commercials&st=cse.
'"' A recent study of continuing-medical-education courses at the University of Wisconsin at
Madison concluded that industry-sponsored continuing education courses offered without
charge to physicians at Wisconsin "frequently advocate prescription medications over drug-
free therapies and omit important information about potentially deadly side effects."
Katherine Mangan, U. of Wisconsin's Industry-Backed Courses Mislead Doctors and Could
Hurt Patients, CHRON. OF HIGHER EDUC. (Mar. 30, 2009), http://chronicle.com/article/U-of-
Wisconsins-Industry-/42653/.
" Id
"^ Nicholas Bakalar, Potential Conflicts Cited in Process for New Drugs, N.Y. TIMES (Oct. 25,
2005),
http://www.nytimes.com/2005/10/25/health/policy/25drug.html?scp=l&sq=Potential+Conflict
s+Cited+in+Process+foH-New+Drugs&st=nyt ("more than one-third of the guideline authors
acknowledged some fmancial interest in the drugs they recommended, including owning stock
and being paid by the company to speak at seminars"; and "in half of the more than 200
guidelines examined, at least one author had received research financing from a relevant
company, and 43 percent had at least one author who had been a paid speaker for the
company.").
*' Miriam Hill, Casting a light on 'off-label' medical devices, PHILADELPHIA INQUIRER, June
23, 2009, p. C1. Pfizer recently pleaded guilty to a felony violation for "misbranding Bextra
with the intent to defraud or mislead," entered into a $2.3 billion settlement with the Justice
Department for illegally marketing of the antibiotic Zyvox, the painkiller Bextra, epilepsy and
nerve pain drug Lyrica, and the antipsychotic Geodon, and "agreed to an 'expansive corporate
integrity agreement' with the Office of Inspector General of the Department of Health and
Human Services" to avoid similar matters in the future. Shirley S. Wang, It's Offtcial: Pfizer
Pleads Guilty to Illegal Marketing of Bextra, WALL ST. J. (July 18, 2010),
http://blogs.wsj.com/health/2009/09/02/its-onicial-pfizer-pleads-guilty-to-illegal-bextra-
marketing/tab/print; Ashley Jones, Pfizer Makes History With $2.3 B Fraud Settlement, WALL
ST. J. (Sept, 2, 2009), http://blogs.wsj.com/law/2009/09/02/pfizer-makes-history-with-23b-
fraud-settlement/tab/print; and Miriam Hill, FDA: Pfizer ignored warnings, gets record fine,
PHILADELPHIA INQUIRER, September 3, 2009, at CI. More recently, on January 15, 2010, Eli
Lilly & Co. entered a guilty plea to charges it illegally marketed the anti-psychotic drug
Zyprexa, and agreed to pay $1.42 billion to settle civil lawsuits and the criminal investigation.
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fully below, drug companies seek to speed products to market as quickly as
possible.''''
The efforts of the pharmaceutical industry to promote drugs for the
treatment of kidney disease typify the first cause. Pharmaceutical companies
Gambro Healthcare and Amgen paid consulting fees to David Van Wyck, a
University of Arizona College of Medicine professor, while he chaired a
National Kidney Foundation panel charged with updating physician
guidelines for treating anemia in kidney patients during 2004 and 2005.''^
Indeed, 12 of the 18 members of the panel chaired by Van Wyck disclosed
financial ties to Amgen, Johnson & Johnson, or other manufacturers or
marketers of antianemia drugs."* After the more liberal prescribing guidelines
for the drug were finalized. Van Wick became a paid consultant to DaVita
Inc., which acquired Gambro in 2005, is the nation's second-largest dialysis
chain, and profits from the use of the drugs in more than 1,200 clinics.''^
Likewise, in 2004, the pharmaceutical company Amgen underwrote
more than $1.9 million worth of research and educational programs led by
Dr. Allan Collins, the president-elect of the National Kidney Foundation.
Amgen made the payments to the Mirmeapolis Medical Research Foundation
(MMRF) pursuant to its research contract with MMRF, for which Dr. Collins
served as senior researcher. The payments triggered concerns, because they
represented a substantial financial connection to an individual closely
associated with the National Kidney Foundation at a time the Foundation was
considering revisions to its guidelines on treating anemia in kidney patients.''^
Similarly, in 2006 the pharmaceutical industry accounted for about 30%
of the annual $62.5 million budget of American Psychiatric Association, the
Eli Lilly settles Zyprexa lawsuit for $1.42 billion, MSNBC (Jan. 15,2009),
http://www.msnbc.msn.com/id/28677805/.
"'' Alice Dembner, Research Integrity Declines, BOSTON GLOBE, Aug. 22,2000, at E2.
'^ Christopher Rowland, Researchers ' advice stirs issue of conflict dispute over care of kidney




•" Id. Similar tactics were used by the five largest U.S. orthopedic firms who manufacture
artificial knees and hips. In September 2007, four of those firms (Zimmer Inc., DuPuy
Orthopaedics, Biomet Inc., and Smith & Nephew) reached a settlement with the Department
of Justice and agreed to pay $311 million in fmes and to release the list of their consultants
and the payments they received. The fifth company, Stryker Orthopaedics, also released a list
of its paid consultants, but was not named in the criminal complaint, because it cooperated
with the federal investigators in the probe. According to the data they released, the five
companies paid more than $200 million to doctors, clinics and university health systems
across the country in 2007, for royalties, clinical trials, and consulting fees. Bill Toland, Are
Doctors Getting Fees or 'Bribes '?, PITTSBURGH POST-GAZETTE (NOV. 7, 2007),
http://www.post-gazette.com/pg/07311/831621 -28.stm.
"** Harris, supra note 31.
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field's leading professional organization, which publishes the field's major
joumals and its standard diagnostic manual. One half of those contributions
purchased dmg advertisements in psychiatric joumals and exhibits at the
Association's annual meeting.'*^ Many psychiatrists eam consulting fees from
the pharmaceutical industry to give dinner talks about dmgs to other
physicians for fees ranging from $750 to $3,500 per event.^" Minnesota and
Vermont, which require pharmaceutical companies to disclose their
payments to physicians in those states, report dmg makers gave more money
to psychiatrists than other specialties and that psychiatrists who received at
least $5,000 from dmg makers of newer-generation antipsychotic dmgs
wrote three times as many prescriptions to children for the drugs as
psychiatrists who received less money.^' Studies have also demonstrated that
researchers who are paid by drug companies are more likely to report
positive findings when evaluating that company's dmg.̂ ^ Further, 19 ofthe
27 members ofthe panel developing the Diagnostic and Statistical Manual of
Mental Disorders ("DSM-V") prepared by the American Psychiatric
Association and scheduled for publication in 2012, reported direct industries
ties to the pharmaceutical companies, an increase of 14% over the percentage
of DSM-IV task force members." DSM-V is the APA's reference book, "the
mental health bible," which recommends "treatment for knovm types of
mental disorders, including what treatments are covered by health-care
providers." '̂* These financial confiicts are dangerous, because:
[DJiagnosis informs treatment decisions. Hence, pharmaceutical
companies have a vested interest in the structure and content of
DSM and in how the symptomatology is revised. Even small
changes in symptom criteria can have a significant impact on what
new (or off-label) medications may be prescribed. Public tmst in
the independence of clinical psychiatry is undermined if former
DSM panel members are using - or a perceived as using - their
participation on DSM to leverage lucrative consulting
arrangements with the Pharmaceutical industry or to funnel
Benedict Carey and Gardiner Harris, Psychiatric Association Faces Senate Scrutiny Over







" Lisa Cosgrove and Harold J. Bursztajn, Toward Credible Conflict of Interest Policies in
Clinical Psychiatry, PSYCHIATRIC TIMES (Jan. 1, 2009),
http://www.psychiatrictimes.com/display/article/10168/1364672.
" Paul Basken, Do Drugs Help Psychiatrists Tune Out Patient Voices?, CHRON. OF HIGHER
EDUC. (Jan. 15, 2009), http://chronicle.com/article/Do-Drugs-Help-Psychiatrists/42250/.
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industry funding to their departments, associates, and programs
(e.g, exerting their influence on prescription practices through
public speaking arrangements, such as industry-sponsored CME
symposia).^^
Perhaps recognizing the dangers posed by medical industry sponsorship
of conferences and association activities, past and current leaders of several
professional medical associations recently advocated ending medical industry
financial support for their conferences in a joint statement published in The
Journal of the American Medical Association, because "such practices
compromise health-care decisions and undermine public trust."^* The leaders
endorsing the statement were associated with the American Psychiatric
Association, American College of Obstetricians and Gynecologists,
American College of Physicians, American Academy of Pediatrics,
American College of Cardiology, and Council of Medical Specialfy
Societies.^^
B. The 1980 Bayh-Dole Act
The second force contributing to the increase of conflicts of interest in
the medical industry is the 1980 Bayh-Dole Act. The Bayh-Dole Act
foments the commercialization of new medical products by creating a
uniform patent policy among the many federal agencies funding research,
and gives academic researchers and their institutions the right to products
developed with goverrmient money. This permits them to license the
inventions to other parties, thereby encouraging them to develop financial
ties to the biotechnology or pharmaceutical industries.^^ Doctors quickly
learned that they could go into business while continuing to practice
medicine.^'
The second force is illustrated by Isador Lieberman, a leading Cleveland
Clinic orthopedic surgeon, who pioneered and promoted a new treatment
known as kyphoplasfy for spinal fi'actures, and simultaneously enjoyed a
'' Cosgrove, supra note 53. In their "Counterpoint" to Dr. Cosgrove, Drs. David Kupfer and
Darrel Begier eschew any such danger, because no wrongdoing has been proved, the
relationships among academic institutions, the government, and the pharmaceutical industry
are collaborative, and the drug industry is regulated by the government. Id.
'^ Paul Basken, Medical-Group Leaders Call for End to Industry Role at Meetings, CHRON. OF
HIGHER EDUC. (Apr. 2,2009),
http://chronicle.com/daily/2009/04/14971n.htm7utm source=at&utm medium=en.
"Id
'' Dembner, supra note 44; Arlene Weintraub and Amy Barrett, Medicine in Conflict, BUS.
WEEK (Oct. 23, 2006),
http://www.businessweek.com/magazine/content/06_43/b4006081.htm.
^' Weintraub, supra note 58.
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decade-long professional association with Kyphon Inc., a Sunnyvale,
California, kyphoplasty equipment manufacturer. Kyphoplasty competes
with its predecessor treatment, vertegroplasty, in spine surgeries primarily on
patients with osteoporosis-related spinal fractures. While both procedures
inject cement into the broken spinal column, kyphoplasty inserts a balloon
device into the compressed vertebra to try to restore its original height, and
then inserts the cement into the cavity. Vertebroplasty is routinely performed
on an outpatient basis with local anesthesia; kyphoplasty requires more
expensive equipment, general anesthesia and overnight hospital stays, and
hence is considerably more expensive that vertebroplasty. Dr. Lieberman
began offering advice to Kyphon shortly after arriving at the Cleveland
Clinic in 1997. He initiated the inaugural work on kyphoplasty in the
Cleveland Clinic in 1999, using equipment provided by Kyphon, and
reported the results of the first 30-patient trial of kyphoplasty in a medical
journal.*" Working with Dr. Mark Reiley, an orthopedic surgeon who
developed the use of a balloon in spinal surgery and co-founded Kyphon Inc.
to develop the instruments used in kyphoplasty. Dr. Lieberman praised the
favorable results obtained in their initial use of kyphoplasty on 26 patients on
the web and permitted data generated from his Clinic procedures to be used
for commercial purposes before being published in medical journals. Dr.
Lieberman accepted Kyphon's invitation to serve on its scientific and clinical
advisory board, and, during his first kyphoplasty trial at the Cleveland Clinic,
was offered stock options in the company, permitting him to purchase
Kyphon stock for $1 per share before the company went public at $15 a
share.*' Lieberman exercised those options in June 2002, subsequently
selling the stock at several intervals between then and January 2005.*^ In
2004, when questions about the safety of the kyphoplasty procedure arose,
largely related to the danger of subjecting elderly patients to trauma and
general anesthesia and the attempts to treat three or more vertebrae at once
because of the higher cost of the procedure. Dr. Lieberman led the rebuttal
for kyproplasty.*^ While promoting and defending kyphoplasty, Lieberman
did not tell his patients about his financial interest in Kyphon unless asked,
and did not reveal his Kyphon stock ownership in the numerous articles he
wrote about kyphoplasty or in his Spring 2005 testimony touting the benefits
of kyphoplasty at a Centers for Medicare and Medicaid Services committee
hearing.*''
°̂ Joel Rutchick, Surgeon kept quiet about stake in company. PLAIN DEALER, Dec. 10, 2006, p.
Al.
"Id
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C. The Rapidly Accelerating Need of the Medical Industry to Conduct
Human Experiments
The third force contributing to an increase in confiicts of interest in the
medical industry is the rapidly accelerating need of the medical industry to
conduct human experiments as part of the drug and medical device approval
process. In the early 1990s, managed care squeezed drug prices, leaving drug
companies with one option: increasing the number of drugs they were
selling. When the drug companies tried to hasten drug development, the
academic world was unable to adapt rapidly, and drug companies began to
recruit private practice doctors to mine their patient base for research
subjects.*^ In short order, the medical industry changed providers of human
subject experiments required as part of the approval process. In 1991, nearly
80% of human experiments were conducted by nonprofit academic medical
centers; by 2000, 40% of the 60,000 human subject studies were conducted
by nonprofit academic medical centers, and 60% were conducted by for-
profit companies, moving more research to "private settings and even
storefront clinics."** Likewise, there has been a significant increase in private
industry funding of medical research that takes place in U.S. universities.
According to a New England Journal of Medicine study, private industry
funds more than two-thirds of medical research at U.S. universities; two
decades ago, the main contributor to medical research was the federal
government.*'
The pressure to accelerate the pace of human experiments is seen most
clearly in two ways: the pharmaceutical industry has increased the bounty it
pays to physician to recruit volunteers for sponsored studies, and physicians
themselves have increasingly engaged in the business of conducting human
experiments. An investigation published by The New York Times reveals:
• Drug companies and their contractors offer large payments to
doctors, nurses and medical staff to encourage the recruitment
patients to enroll in the trials and offer finder fees to physicians
who refer their patients to other doctors for research; fees paid
to physicians for an enrolled patient ranged from $3,500 to
" Kurt Eichenwald and Gina Kolata, Drug Trials Hide Conflicts for Doctors, N.Y. TIMES
(May 16, 1999), http://www.nytimes.com/1999/05/16/business/drug-trials-hide-conflicts-for-
doctors.html.
" Dembner, supra note 44.
" Alicia Chang, Study identifies conflicts in med school research. STAR LEDGER, May 26;
2005, at 63.
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$5,000, enabling some physicians to net between $500,000 and
$1 million per year doing clinical research.
• Physicians who successfully recruit the most patients are
offered the opportunity to ghost write the papers published
about the research.
• Testing companies frequently use physicians as clinical
investigators regardless of their specialty, leaving the patient
volunteers in the study to the care of a physician who is not
knowledgeable about the patient's condition.
• Physicians conducting clinical investigations increasingly have
little experience as clinical investigators.*^
The shift to private industry providers of drug studies is demonstrated
by the following New York Times data: in 1997, 11,662 private doctors
conducted drug studies, a threefold increase since 1990, when 4,307 doctors
conducted such studies.*' Satisfied with the responsiveness and flexibility of
private physicians who "sign contracts overnight, advertise widely, offer
financial incentives for patients and open their offices at unusual times to
accommodate patient schedules,"'" the drug industry has begun to
aggressively recruit doctors to "grab their piece of the research pie."'' As the
number of physicians conducting research has increased, the average number
of studies conducted by physicians has decreased (e.g., during the 1990s,
70% of the doctors conducting human experiments were involved in three or
fewer drug studies; in 1997, one-quarter of the doctors conducted only one
experiment).'^ This means that an increasing number of physicians
conducting drug testing have little or no experience in doing so, and, with the
increase in the number of generalist physicians engaged in research, doctors
conducting clinical trials often have no expertise in the disease they are
investigating.'^ Nonetheless, they receive several thousand dollars in
compensation per patient for examining and monitoring as many as 24 trial
participants over the course of several months.'"
Eichenwald, supra note 65.
"Id.
'•* Keith Darci, Drug companies rely on volunteers to test their wares, SAN DIEGO UNION-
TRIBUNE, May 19, 2008, Today's Scene.
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While the pressure to increase the pace of human experiments has
increased, a study of the institutional review board policies at medical
schools that receive funding from the National Institutes of Health
demonstrates that fewer than half of those policies cover the topic of using
finder fees or bonus payments to help recmit study participants.'^ In the
absence of those policies, researchers "might otherwise be tempted to enroll
ineligible study participants."'*
VI. RELATED CHANGES IN MEDICAL RESEARCH
The significant increase in private industry dmg studies has spawned
three other changes in medical research: medical company contributions to
nonprofit foundations associated with for-profit medical practices, ghost
writing in medical research, and the celebrity medical expert.
A. Contributions to Physicians ' Nonprofit Foundations
Physicians in private practice have begun to establish tax-exempt
charities to engage in medical research or education, and dmg and medical
device companies are making significant contributions to these nonprofit
organizations." While the nonprofit organizations are separate entities, they
are closely linked to physicians' medical practices. Typically, medical
companies contribute frinds to the nonprofit organizations to support medical
research and educational programs. For example:
• CHF Solutions, a medical device company, contributed
$180,000 to the Midwest Heart Foundation, a charitable
organization associated with a thriving for-profit medical group
outside of Chicago, which uses many of the products made by
CHF Solutions. CHF Solutions' contribution represented about
10% of the contributions received by the Midwest Heart
Foundation during 2004.
• Orthopedic device company Stryker contributed $200,000 to the
Arizona Orthopedic Education Foundation. Its founder, Anthony
K. Hedley, uses mainly Stryker devices with his own patients.
" Paul Basken, Universities Face Conflict-of-interest Questions Over Finder Fees for Study
Participants, CHRON. OF HIGHER EDUC. (Mar. 19, 2009),
http://chronicle.com/article/Lfniversities-Face/42592/.
"Id.
" Reed Abelson, Charities Tied to Doctors Get Drug Industry Gifts, N.Y. TIMES (June 28,
2006), http://www.nytimes.com/2006/06/28/business/28foundation.html.
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• DePuy Orthopaedics, a unit of Johnson & Johnson, contributed
$75,000 to the Blue Ridge Bone and Joint Research
Foundation, headed by Joseph T. Moskal, an orthopedic
surgeon in Roanoke, Virginia. Those funds were used to offset
the costs of a fellowship program permitting physicians to train
in orthopaedic surgery performed in his medical practice.
• Medical device makers Guidant and Medtronic contributed
funds to the Vascular Specialists Education Foundation headed
by Marc H. Glickman, which uses those funds to support
training of physicians and fellows on vascular disease
procedures.^^
To the extent these contributions are actually used for the foundation's
charitable purpose (research and education), there would appear to be no
problem. To the extent, however, these funds are used to subsidize or offset
expenses of the medical practice (e.g., using fellowship funds to underwrite
medical practice salary expenses), significant tax and conflict of interest
issues and problems are created.
B. Ghost Writing Scientific Research
Senator Grassley described the practice of medical ghost writing in his
inquiry to Wyeth Laboratories and press release dated December 12, 2008:
Over the last year, the Committee has been examining a practice
used by drug companies referred to as "medical ghostwriting." I
have been informed that this practice involves marketing and/or
medical education companies that draft outlines and/or manuscripts
of review articles, editorials, and/or research papers. This
information is then presented to prominent doctors and scientists,
particularly those affiliated with academic institutions, to review,
edit and sign on as authors, whether or not they are intimately
familiar with the underlying data and relevant documentation. In
addition, it is not always apparent in the publication that
individuals and companies other than the listed authors were deeply
involved in the study and/or drafting of the final manuscript.
Articles published in medical journals are widely read by
practitioners, and relied upon as being unbiased and scientific in
"M.
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nature. Concerns have been raised, however, that some medical
literature may be subtle advertisements rather than publications of
independent research. The information in these articles can have a
significant impact on doctors' prescribing behavior and, in turn, on
the American taxpayer, because the Medicare and Medicaid
programs pay billions of dollars for prescription drugs. Thus, any
attempt to manipulate the scientific literature, that can in turn
mislead doctors to prescribe drugs that may not work and/or cause
harm to their patients, is very troubling."
In his letter to Wyeth, Senator Grassley notes that documents uncovered in
recent litigation involving Wyeth's hormone therapy products raise questions
about the role of Design Write Inc. in devising, writing and obtaining
academic investigators to sign on as the primary authors of articles appearing
in American Journal of Obstetrics and Gynecology, Obstetrics and
Gynecology, and Primary Care Update for OB/GYNs. "
This is not the first venture of Wyeth in medical ghost writing. Wyeth
paid Excerpta Medica Inc. $40,000 to write ten articles supporting the use of
the "fen" half of the "fen-phen" drug combination. Excerpta retained well-
known university researchers to edit drafts and lend their name to the final
work in exchange for $1,000 to $1,500 honoraria.^' Two of the ten articles
were published in the American Journal of Medicine and Clinical
" Letter fi-om U.S. Senator Charles Grassley, to Bernard J. Poussot, Chairman, President and
Chief Exec. Officer, Wyeth from (Dec. 12, 2008)
(http://finance.senate.gov/newsrooni/ranking/download/?id=d80f46b5-d896-41b8-a7ae-
136d7ec5a431 ); See Paul Basken, Ghostwriters Haunt the Integrity of Medical Journals,
CHRON. OF HIGHER EDUC. (Sept. 14, 2009), http://chronicle.coni/article/Ghosts-Haunt-the-
Integrity-of/48365/?sid=at&utm_source=at&utm_medium=en ("The practice raises the specter
of hidden bias in published papers that favor the effects of the company's drugs. Doctors rely
on such papers when making life-or-death choices about treating their patients.")
'" Grassley, supra note 79. Citing three Columbia University researchers who signed their
names to articles financed by Wyeth, Senator Grasley subsequently recommended that NTH
combat the practice of university researchers engaging in ghostwriting of drug company
research articles. Sen. Grassley Presses NIH Over Ghostwritten Research Reports, CHRON. OF
HIGHER EDUC. (Aug. 19, 2009), http://chronicle.com^logPost/Sen-Grassley-Presses-NIH-
Over/7741/?sid=pm&utm_source=pm&utm_medium=en. Wyeth also recruited a McGill
University professor to contribute a ghostwritten article to the Journal of the American
Geriatrics Society. In her article. Professor Barbara Sherwin "argued that estrogen could help
treat memory loss in older patients." Lawyers representing clients suing Wyeth for harms
caused by its hormone drugs have discovered 26 ghostwritten research papers in 18 medical
journals. Paul Basken, Professor at Canada's McGill U. Admits Signing Research Generated
by Drug Maker, CHRON. OF HIGHER EDUC. (Aug. 11, 2010),
http://chronicle.com/article/McGill-U-Professor-
Admits/48164/?sid=at&utm_source=at&utm_medium=en.
" Research Ethics: Paying MDs to 'Write' Fen-Phen Articles, AM. HEALTH LINE (May 24,
1999), http://www.americanhealthline.eom/archives/1999/05/m990524.9.html.
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Therapeutics. The remaining eight articles were never published, because
the fen-phen drugs were pulled from the market after studies linked them to
heart-valve damage and an often-fatal lung disease.^^
Martin Keller, Professor of Psychiatry and Human Behavior and
chairman of the psychiatry department at the Alpert Medical School of
Brown University, and his coauthors were accused by doctors, lawyers, and
journalists of permitting their names to be added as authors of the 2001
ghostwritten study of the antidepressant drug Paxil that concluded the drug
was safe and effective in adolescents.*^ Their article became one of the most
cited medical articles supporting the use of antidepressants in adolescents,
and prompted Paxil manufacturer GlaxoSmithKline to promote the use of the
product among children, an untapped market for antidepressants.^'' More
recent studies, however, demonstrate Paxil can lead to increased suicidal
tendencies in children, and Keller subsequently acknowledged receiving
consulting fees in the tens of thousands of dollars from GlaxoSmithKline.*^
Further, because of the increase in private industry funding of medical
research at U.S. universities - private industry funds more than two-thirds of
medical research at U.S. universities - concerns have also been raised about
the control ceded by universities to private companies sponsoring the
research over the results attained in the study. A recent survey shows many
of the top medical school in the United States have no clear policies
prohibiting medical ghostwriting; only thirteen of the top fifty medical
schools have such policies.** A study conducted by the Harvard School of
'^ Charles Omstein, Evidence in fen-phen suit claims drug maker had hand in journal articles.
THE DALLAS MORNING NEWS, May 22,1999.
" Chaz Firestone and Chaz Kelsh, Senator targets Brown U. professor's ties to bigpharma,
CBS NEWS (Sept. 23,2008),
http://www.cbsnews.com/stories/2008/09/24/politics/uwire/main4473367.shtml.
GlaxoSmithKline instructed its salespeople to offer assistance to physicians to write and
publish articles about the helpfulness of Paxil. The offered assistance covered all facets from
selecting a topic, writing the report, and submitting the article for publication. Matthew
Perrone, Glaxo used ghostwriting program to promote Paxil, PHILADELPHIA INQUIRER, (Aug.
20, 2009), http://abcnews.go.com/Health/Business/wireStory?id=8366574.
"Id.
" Id. GlaxoSmithKline also paid consulting fees to a reviewer of an article submitted to New
England Journal of Medicine reporting a link between heart attacks and the drug Avandia
manufactured by GlaxoSmithKline. The reviewer faxed an advance copy of the manuscript to
GlaxoSmithKline, prompting Senator Charles Grassley to request information from
GlaxoSmithKline describing what it did after receiving the advanced copy. Letter from
Senator Charles Grassley, to GlaxoSmithKline (Jan. 30, 2008) (
http://flnance.senate.gov/newsroom/ranking/release/?id=33317a8c-ad81-43bb-8ed6-
2acff4e45a46).
" Few Top Medical Schools Ban Ghostwriting by Researchers, Survey Finds, CHRON. OF
HIGHER EDUC. (Feb. 1, 2010), http://chronicle.com/blogPost/Few-Top-Medical-Schools-
Ban/20990/?sid=at&utm source=at&utm medium=en.
290/Vol. XXII/Southern Law Journal
Public Health and appearing in the New England Journal of Medicine,
demonstrates that, while medical schools overwhelmingly agreed they would
not enter into contracts that would allow companies to edit research articles
or suppress negative results, 50% would permit companies to draft research
papers and 25% would permit them to provide the data.^' Indeed, a recent
study indicates that ghostwriting research articles "is distressingly common
in top medical journals."^^ The study, presented at the Sixth Annual
Conference on Peer Review and Biomédical Publication, "found the
prevalence of 'ghost' authors at top-ranked medical journals ranged last year
from 2 percent at Nature Medicine to 11 percent at The New England Journal
of Medicine," and that 7.8% of all articles from 2008 published in Nature
Medicine, The New England Journal of Medicine, Annals of Internal
Medicine, the Journal of the American Medical Association, The Lancet, and
PLoS Medicine had at least one ghost author.^' Perhaps stung by the
negative publicity about ghostwritten articles. The New England Journal of
Medicine, The Lancet, and the Journal of the American Medical Association
have announced that they plan to require the disclosure by authors of
possible conflicts of interest in their research by utilizing a uniform
disclosure form of al] actual and potential financial conflicts of interest.'"
C. The Rise of the Celebrity Medical Expert
The rise of the celebrity medical expert is the third offshoot stemming
from the increase in private industry drug studies. For example. Lisa Hark
parlayed her work in the nutrition education program at the University of
Pennsylvania medical school, her experience as host of television nutrition
programs, and her authorship of a widely used and award winning nutrition
textbook into a successful consulting practice in the field of nutrition. The
Florida orange industry hired her to promote the health benefits of orange
juice in a six-month, $24,800 contract that produced "more than 132 million
media impressions," including a Forbes magazine quote in which Hark touts
" Alicia Chang, Drug Companies Influence Medical Research, EXCITE NEWS (May 25, 2005),
http://www.biopsychiatry.com/bigpharma/influence.html; See Michelle M. Mello et al..
Academic Medical Centers ' Standards for Clinical-Trial Agreements with Industry, NEW ENG.
J. MED. (May 26, 2005), http://content.nejm.org/cgi/content/nill/352/21/2202.
" Paul Basken, Medical 'Ghostwriting' Is Still a Common Practice, Study Shows, CHRON. OF
HIGHER EDUC. (Sept. 10, 2009), http://chronicle.com/article/Medical-Ghostwriting-Is-
a/48347/?sid=at&utm source=at&utm medium=en.
"Id
' " Medical Journals Tighten Rules on Author Conflicts, CHRON. OF HIGHER EDUC. (Oct. 14,
2009), http://chronicle.com^logPost/Medical-Joumals-Tighten-
Rules/8448/?sid=pm&utm_source=pm&utm_medium=en; The uniform disclosure form was
accessed on July 21, 2010, at http://www.icmje.org/coi_disclosure.pdf.
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the benefits of orange juice for preventing colds and the flu." Hark also
provided a helpful comment to Tyson Foods campaign to promote its
chickens as being "raised without antibiotics," saying "This is great news for
American consumers who have made it clear they pay attention to the use
and presence of all sorts of antibiotics in the environment."'^ The U.S.
Department of Agriculture later ordered Tyson Foods to stop using the
"raised without" label after Tyson Foods admitted it injected eggs with
antibiotics. Working for the National Dairy Council, Hark advocated the
benefits of consuming three servings of low-fat dairy a day.'^ Hark's website
invites companies to engage her services as a nutritionist with the words:
Are you looking for a media expert to help promote and market
your company? Do you want to add credibility to your brand,
consult with a nutrition expert, hire a spokesperson or develop an
Advisory Board? Dr. Lisa Hark has the academic background and
media experience to help your company successñilly reach both
consumers and health professionals.''*
Similarly, psychiatrist Frederick K. Goodwin, the host of NPR's popular
program "The Infinite Mind," admitted eaming at least $1.3 million from
2000 to 2007 giving marketing lectures for dmgmakers.'^ "The Infinite
Mind" has won more than 60 joumalism awards and generated over one
million listeners in more than 300 radio markets.'* Goodwin's weekly radio
program frequently addressed topics important to the fmancial interests of
companies for which he consulted." For example, on September 20, 2005,
Goodwin advised his audience that children with bipolar disorder who were
not treated could suffer brain damage and that mood stabilizers have proven
to be safe and effective in bipolar children. That same day, GlaxoSmithKline
paid him $2,500 to give a promotional lecture for GlaxoSmithKline's mood
stabilizer dmg, Lamictal, at the Ritz Carlton Golf Resort in Naples, Florida,
part of the $329,000 it paid him during 2005 to promote Lamictal.'^ In
another segment of his show, Goodwin denied the existence of scientific
evidence of a link between antidepressants and increased risk for suicidal
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behavior, while receiving $20,000 fi-om GlaxoSmithKline for a promotional
lecture for Lamictal." While Goodwin claimed he informed Bill
Lichtenstein, the program producer, of his fmancial ties to drugmakers.
Lichtenstein denies being aware of those ties.'"" When the drug industry
consulting arrangements with Goodwin became public, Margaret Low Smith,
vice president of NPR, announced that the show would be removed from its
satellite radio service the following week, the earliest date possible, and NPR
would never have broadcast the show it if had known of Goodwin's
conflicting fmancial interests.""
VTI. RESPONSE OF MEDICAL INSTITUTIONS AND ACADEMIC
ORGANIZATIONS
The vast array of confiict of interest revelations uncovered by Senator
Grassley produced swift responses fi'om medical institutions and academic
organizations. Harvard Medical School and Massachusetts General Hospital
announced they would investigate doctors' disclosure and conflict of interest
forms and re-examine their policies on the relationships between physicians
and industry.'"^ Harvard Medical School faculty and students subsequently
formed a nineteen member committee to re-examine the school's conflict of
interest policies, and engaged David Kom, the former dean of Stanford
University, who assisted the American Medical Association in drafting a
conflict-of-interest policy for medical schools, as a consultant to the
committee.'"^ The University of Mirmesota approved a tougher financial
conflicts of interest policy, which requires faculty and staff to disclose all
financial interests, which "an independent observer might reasonably
question whether the individual's objectivity in the performance of
" Id.\ NPR Radio Host Failed to Disclose Payments, AM. HEALTH LINE (NOV. 24, 2008),
http://www.americanhealthline.com/search.aspx7query=NPR+Radio+Host+Failed+to+Disclos
e+Payments&topic=&.
'*"' Harris, supra note 95; Am Health Line, supra note 99.
'**' Harris, supra note 95.
"" Harvard doctors ' studies tainted, PITTSBURGH TRIB. REV. (June 9, 2008),
http://www.pittsburghlive.com/x/pittsburghtrib/news/breaking/s_571718.html; June Q. Wu,
Harvard medical school to reexamine conflicts of interest policy, HARVARD CRIMSON (June
16, 2008), http://www.thecrimson.eom/article/2008/6/l6/barvard-medical-school-to-
reexamine-conflicts/.
'"' Katherine Mangan, Harvard Medical Students and Faculty Members Work to Expose
Conflicts of Interest, CHRON. OF HIGHER EDUC. (Mar. 3,2009),
http://chronicle.com/article/Harvard-Medical-Students-an/42501. See Charles Huckabee,
Sen. Grassley Asks Pfizer .4bout Payments to Faculty Members at Harvard Medical School,
CHRON. OF HIGHER EDUC. (Mar. 3, 2009), http://chronicle.com/article/Sen-Grassley-Asks-
Pfizer/42505 ("The Iowa senator is asking the drug maker Pfizer to provide details of its
payments to at least 149 faculty members at Harvard Medical School").
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University responsibilities could be compromised by considerations of
personal gain," and prohibits those individuals from engaging in University-
related activities in which a conflict of interest exists.'°'' Michigan Medical
School has announced that it will stop taking money from drug or medical-
device manufacturers to pay for the refresher courses that doctors must take
to renew their licenses.'"' The Journal of the American Medical Association
published a correction listing sixty-four financial ties between the authors of
published articles and manufacturers of antidepressant drugs, and revised its
conflict of interest policy to require authors to divulge any financial ties they
may have to the medical industry in an acknowledgement section.'"* The
Federation of American Societies for Experimental Biology, which
represents 84,000 research scientists, issued a report containing a suggested
set of voluntary guidelines to assist scientists identify and manage conflicts
of interest.'"' Two medical organizations, the Institute on Medicine as a
Profession (IMAP) and the Association of American Medical Colleges,
announced they would launch websites detailing conflict of interest policies
instituted by academic medical centers.'"^ IMAP's website is up and running,
contains the conflict of interest policies of over 125 medical institutions, and
can be accessed at http://www.imapny.org/policy/. The Cleveland Clinic
announced that the financial links between its 1,800 physicians and
researchers will be published on the clinic's website as part of its effort to
minimize conflicts of interest. "" The University of Pennsylvania School of
'"'' Paul Basken, Minnesota Regents Outline Policy to Toughen Rules on Financial Conflicts of
Interest, CHRON. OF HIGHER EDUC. (Mar. 12, 2010), http://chronicle.com/article/Minnesota-
Regents-Outline/64668/?sid=at&utm_source=at&utm_medium=en. The text of the policy
approved by the Board of Trustees on March 12, 2010, appears in the minutes of their meeting
accessed on July 20, 2010, at http://wv*iwl.umn.edu/regents/docket/2010/march/board.pdf.
'"' Medical School Bans Industry Contributions for Continuing-Medical-Education Courses,
CHRON. OF HIGHER EDUC. (June 23, 2010), http://chronicle.com^logPost/Medical-School-
Bans-Industry/25050/?sid=at&utm_source=at&utm_medium=en.
'"* Katherine Mangan & Jeffrey R. Young, Medical Journal Toughens Its Conflict-of-interest
Policy, CHRON. OF HIGHER EDUC. (July 21, 2006), http://chronicle.com/article/Medical-
Joumal-Toughens-Its/19274.
"" Jeffrey Brainard, Biomédical Group Will Suggest Ways for Scientists to Handle Potential
Conflicts of Interest, CHRON. OF HIGHER EDUC. (July 28,2006),
http://chronicle.com/article/Biomedical-Group-Will-Suggest/7728.
'" Shawn Rhea, AAMC, institute ready online guides to centers' conflict-of-interest policies,





'*" Katherine Mangan, Cleveland Clinic to Divulge Scientists ' Industry Ties, CHRON. OF
HIGHER EDUC. (Dec. 2, 2008), http://chronicle.com/news/article/5594/cleveland-clinic-to-
divulge-scientists-industry-ties?utm_source=at&utm_medium=en; Reed Abelson, Cleveland
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Medicine and health system announced it would launch a website disclosing
searchable information on all outside activities of its doctors and scientists.""
The American Psychiatric Association announced that it will no longer
permit drug companies to provide education seminars and meals at its annual
meeting.'" The National Academies' Institute of Medicine issued a 353-
page report calling on "medical schools, hospitals, and physicians' groups to
publicly report money they receive from drug companies, to not accept free
gifts or meals from the industry, and to ban physicians who have fmancial
confiicts of interest from testing new therapies on people.""^ These
responses, however, fall well short of the more comprehensive policy
proposal developed by the American Medical Association, discussed below.
VIII. SOLUTIONS PROPOSED TO COMBAT MEDICAL INDUSTRY
CONFLICTS OF INTEREST
Three major solutions have been proposed to combat the medical
industry confiicts of interest detailed above in this case. The first solution is
embodied in the Physician Payments Sunshine Act, which requires
companies manufacturing drugs, medical devices or medical supplies to
make quarterly reports to the Secretary of Health and Human Services
detailing payments made to physicians or their employers, and prohibits tax
deductions for advertising, promotion or marketing expenses for any
payments not disclosed."^ The reported information, in turn, will be
published in the federal register permitting patients and consumers the
Clinic Discloses Doctors ' Industry Ties, N.Y. TIMES (Dec. 2, 2008),
http://www.nytimes.eom/2008/l 2/03/business/03clinic.html?fta=y.




' ' ' Josh Fischman, Psychiatrists Say No to Drug Company Events at Their Annual Meeting,
CHRON. OF HIGHER EDUC. (Mar. 26, 2009), http://chronicle.com/article/Psychiatrists-Say-No-
to-Dru/42636/ ("The American Psychiatric Association said yesterday that it would no longer
allow education seminars and meals sponsored by pharmaceutical companies at its annual
meeting").
' '̂  Katherine Mangan. Institute of Medicine Calls for Ban on Drug-Company gifls to
Professors and Others, CHRON. OF HIGHER EDUC. (Apr. 28, 2009),
http://chronicle.com/article/Institute-of-Medicine-Calls/42815/.
"' The Physician Payments Sunshine Act of 2008, H.R. 5605, 110th Cong. (2008),
http://www.govtrack.us/congress/bill.xpd?bill=hl 10-5605. A more comprehensive version of
the Physician Payments Sunshine Act was introduced on January 20, 2009. See Press Release,
Grassley Works to Disclose Financial Ties Between Drug Companies and Doctors (Jan. 22,
2009) (http://grassley.senate.gov/news/Article.cfm?customel_dataPageID_l 502=18901#).
The Physician Payments Sunshine Act of 2009, S. 301, 111th Cong. (2009),
http://www.govtrack.us/congress/bill.xpd7bilNsl 11-301.
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opportunity to learn about medical industry conflicts of interest, and thereby
augmenting transparency and accountability for the various payments made
to physicians."" Notably, a significant number of medical companies and
organizations have endorsed the Physician Payments Sunshine Act."^
Moreover, perhaps realizing the inevitability of public disclosure, Eli Lilly,
GlaxoSmithKline, Merck, and Pfizer have agreed to publicly disclose
payments they make to doctors."*
The public disclosure approach contained in the Physician Payments
Sunshine Act and conceded by several major pharmaceutical firms, however,
is only one-half of the normal legal resolution recommended for conflicts of
interest within corporate governance. More particularly, when directors or
officers fmd themselves in a conflict of interest, they must make full
disclosure of the conflict and refrain from any participation in the transaction
approval process. The latter requirement - not participating in the transaction
' '"* See More disclosure needed on drug company payouts, DENVER POST (Aug. 10, 2007),
http://www.denverpost.com/search/ci_6586804.
' ' The following organizations have endorsed the Physician Payments Sunshine Act:
American Medical Association, Association of American Medical Colleges, AdvaMed,
Pharma, Abbott and Abbott Lab, Amgen, Astra Zeneca, Baxter, Boston Scientific, Bristol
Myers Squibb, Eli Lilly, Johnson and Johnson, Medtronic, Inc., Merck, Pfizer, St. Jude
Medical, Stryker, Wyeth, and Zimmer Holdings. Press Release, Support for S. 2029, the
Grassley-Kohl Physicians Payments Sunshine Act (July 20, 2010)
(http://fmance.senate.gov/newsroom/ranking/release/?id=e869c734-de40-4b4f-9b7e-
fd9d5d742c87). The following companies support the disclosure of financial contributions to
continuing medical education: Baxter, Medtronic, Boston Scientific, Merck, Pfizer, St. Jude
Medical, Abbott Lab, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson,
Schering-Plough, Stryker, Wyeth, and Zimmer Holdings. Press Release, Responses From
Pharmaceutical Drug and Device Makers to Grassley Request for Disclosure of Support for
Continuing Medical Education (Apr. 11, 2008)
(http://finance.senate.gov/newsroom/ranking/release/?id=637bd77c-508f-489d-84fd-
133c94e6ea3b).
'" In September 2008, Eli Lilly began disclosing on its website payments to doctors who
serve as consultants. Shirley S. Wang, Eli Lilly's Payments to Doctors Revealed, WALL ST. J.
(July 31, 2009), http://blogs.wsj.com/health/2009/07/31/eli-lillys-payments-to-doctors-
revealed/tab/print/. Pfizer, GlaxoSmithKline, and Merck have also agreed to disclose
payments made to doctors. See Linda A. Johnson, Pfizer to disclose payments to doctors next
year. COURIER POST (Feb. 10, 2009),
http://seattletimes.nwsource.com/html/health/2008726701_pfizerl0.html ("Pfizer Inc., the
world's biggest drugmaker, said Monday it will begin disclosing all sizable payments it makes
to doctors, including those who test experimental drugs in people, a first for the industry. The
disclosures would begin early next year and are plarmed to include all payments to medical
personnel who prescribe drugs — doctors, physician's assistants and nurse-practitioners —
exceeding $500 in a year, the New York-based company told The Associated Press."); Maria
Panaritis, Glaxo to change training-payment practices, PHILADELPHIA INQUIRER (Sept. 22,
2009), http://www.allbusiness.com/education-training/curricula-medical-
education/13010850-l.html 1 ("By year's end, Glaxo said, it also would begin publicly
disclosing all payments it makes to doctors. . . . In September 2008, drugmakers Merck &
Co., and Eli Lilly & Co., said they would begin publicly disclosing payments to physicians").
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approval process - is not explicitly included in the Physician Payments
Sunshine Act. Significantly, in at least one instance, public disclosure of
conflicts of interest resulted in the removal of members ofthe FDA advisory
committee charged with determining whether an extended-release version of
pharmaceutical company AstraZeneca's Seroquel XR, a powerftil
antipsychotic used to treat depression and anxiety, should be approved.
Jorge Armenteros, the chair and a voting member ofthe committee, who was
paid by AstraZeneca to promote the dmg in talks to other doctors, and four
other committee members, were removed from the committee because of
conflicts of interest made public by attomeys representing patients who are
suing AstraZeneca and other makers of antipsychotics and claim the drugs
triggered their diabetes.'" The FDA panel, meeting without the five
removed members, approved a limited use for Seroquel XR as an additional
therapy for patients suffering from depression who do not respond to their
current medications, and declined to approve the broader use requested by
AstraZeneca to treat depression and anxiety as a single therapy. Approval of
the broader use of Seroquel XR would have "dramatically expanded the
market for Seroquel," which currently generates $4.7 billion in annual
sales. "^
The second proposed solution is the creation of a National Institute of
Dmg Testing (NIDT). The principal justifications advanced for this proposal
are threefold: (1) "endemic" conflicts of interest in the system of dmg
evaluation have "been exacerbated by the rise in for-profit clinical trials, fast-
tracking of dmg approvals, government-industry partnerships, direct
consumer advertising, and industry-ftinded salaries for FDA regulators;" (2)
"those who manufacture and market products should not have undue
influence and control over how the product is evaluated;" and (3) the concept
of "independent science" should be reintroduced in dmg testing to "prevent
even the appearance of confiict of interest.""' Under this proposal, the
NIDT will be added to NIH and charged with the responsibility of
independently testing the efficacy and safety of drugs and medical devices.'^"
While medical companies can continue to pre-test dmgs and medical devices
using their own scientists or contracted researchers, the medical companies
must submit the drug or device to NIDT for testing, thereby creating a
"buffer" or "firewall" between drug companies and researchers who test
dmgs in animals or in human subjects.'^' NIDT will be fmanced by fees paid
' " Miriam Hill, Conflict for FDA panel on Seroquel, PHILADELPHIA INQUIRER (Apr. 4. 2009),
http://bipolarsoupkitchen-stephany.blogspot.com/2009/04/conflict-of-interest-fda.html.
' " Miriam Hill, A minor victory in Seroquel battle, PHILADELPHIA INQUIRER (Apr. 8, 2009),
http://www.philly.com/philly/business/42724807.html.
' " Krimsky, supra note 37.
""Id.
'" Id.
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by the drug companies based on accepted research costs set by the institute;
the NIDT will solicit qualified scientists to conduct the tests subject to
protocols designed to protect the confidentiality of business information; and
data fi-om test results will be made fully accessible to the drug companies,
health care providers and the general public.'^^
The third proposal is the far more comprehensive policy developed by
the American Medical Association and aimed at academic medical centers.
In issuing its proposed policy, the AMA noted that the "standing of the
profession, as much as the integrity of the pharmaceutical and medical device
industries, is jeopardized by allowing obvious conflicts to continue," and that
academic medical centers "must more strongly regulate, and some cases
prohibit, many common practices that constitute conflicts of interest with
drug and medical device companies."'^^ The AMA preliminarily emphasized
that a wide range of psychological, sociological, and economic research
demonstrates that even small gifts significantly influence physicians'
behavior and that public disclosure of conflicts of interest alone is
insufficient to satisfy the need to protect the interests of patients.'^'' The
AMA policy recommends:
• All gifts (zero dollar limit), free meals, payment for time for
travel to or time at meetings, and payment for participating in
online [continuing medical education] fi^om drug and medical
device companies to physicians should be prohibited.
• The direct provision of pharmaceutical samples to physicians
should be prohibited and replaced by a system of vouchers for
low income patients or other arrangements that distance the
company and its products ft-om the physician.
• Hospital and medical group formulary committees and
committees overseeing purchases of medical devices should
exclude physicians (and all health care professionals) with
financial relationships with drug manufacturers, including those
who receive any gift, inducement, grant or contract.
• [Drug manufacturers] should not be permitted to provide support
directly or indirectly through a subsidiary agency to any
[academic center continuing medical education]-accredited
program. Manufacturers wishing to support education for
"'Id.
' " Brennan, supra note 7, at 429-33.
"' Id. at 430.
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medical students, residents, and/or practicing physicians should
contribute to a central repository . . . which, in turn, would
disburse the funds to ACCME-approved programs.
• Pharmaceutical and device manufacturers interested in having
faculty or fellows attend meetings should provide grants to a
central office at the AMC. That office could then disburse funds
to faculty and training program directors.
• Faculty at AMCs should not serve as members of speakers
bureaus for pharmaceutical or device manufacturers. Speakers
bureaus are an extension of manufacturers marketing apparatus.
Because AMC faculty have a central role in training of new
physicians and represent their own institution, they should not
function as paid marketers or spokespersons for medicine-related
industries.
• [CJonsulting with or accepting research support from industry
should not be prohibited. However, to ensure scientific integrity,
far greater transparency and more open communication are
necessary. Accordingly, consulting or honoraria for speaking
should always take place with an explicit contract with specific
deliverables, and the deliverables should be restricted to
scientific issues, not marketing efforts. So-called 'no strings
attached' grants or gifts to individual researchers should be
prohibited.
• AMCs should be able to accept grants for general support of
research (no specific deliverable products) from pharmaceutical
and device companies provided that the grants are not designated
for use by specific individuals.
• [C]onsulting agreements and unconditional grants should be
posted on a publicly available internet site, ideally at the
academic institution.'^^
'"/£/. at 431-32.
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IX. POTENTIAL DISCUSSION QUESTIONS
A. Do payments by medical industry companies to practicing physicians and
medical school department heads create conflicts of interest?
The payments by medical industry companies to practicing physicians
and medical school department heads in the form of free meals and drug
samples, travel expenses to attend professional meetings or continuing
education programs, payments for consulting, lectures, and enrolling patients
in clinical trials, donated research equipment, fmancial support for residency
and fellowship training, and service on advisory boards, do create confiicts of
interest. Having accepted those financial benefits, the practicing physicians
and academic department heads cannot be said to be acting solely for the
benefits of their patients or their academic employers. Whenever a
reasonable observer cannot ascertain with certainty what motivated the
physician to recommend a medical treatment (best interest of the patient or
gratitude to a medical company) or the academic department head to
undertake medical research (best scientific answer or best outcome for the
medical company), a material confiict of interest exists, and the public
interest in guaranteeing the safety and effectiveness of medical treatments
and devices is threatened.
B. Do the failures of Drs. Schatzberg, Wang, Biederman, and Nemeroff to
disclose fully their financial interests and ties to medical industry companies
violate their fiduciary obligations as employees respectively of Stanford,
UCLA, Harvard and Emory Universities?
As employees of Stanford, Harvard, Emory, and UCLA, Drs.
Schatzberg, Biederman, Nemeroff and Wang owe multiple fiduciary duties to
their employers: (a) to use reasonable diligence and skill in performing their
duties, (b) to notify their employers of all information that comes to their
attention and is relevant to the employment relationship, (c) to act solely for
the benefit of their employers, (d) to follow all lawful and clearly stated
instructions given to them by their employers, and (e) to account for all
property and funds received and expended on behalf of the employer.'^*
Their failure to disclose fully their financial ties to medical industry
companies violates three of those duties. First, they failed to notify their
employee of the true extent of their financial links to the medical industry
companies, and that failure not only prevents the four physicians from
fulfilling their employment obligations but also causes their employers to
'̂ * Cross, supra note 1, at 485-86; Restatement (Third) of Agency §§ 8.01, 8.02, 8.07, 8.08,
8.09(2), 8.10, and 8.11.
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suffer significant damages in the form of lost external research funding and
future research funding opportunities, doubts about the reliability of research
undertaken by the University's medical scientists, and significant distractions
as the universities respond to inquiries of the U.S. Senate Finance Committee
and various news organizations. Second, Drs. Schatzberg, Wang, Biederman,
and Nemeroff breached their fiduciary obligation to act solely for the benefit
of their employer by accepting financial contributions and holding financial
interests in medical industry companies and failing to disclose same. From
that moment on, Drs. Schatzberg, Wang, Biederman, and Nemeroff placed
their own fmancial interests and the interest of the medical industry
companies above the interest of their employers. Third, Drs. Schatzberg,
Biederman, Nemeroff and Wang failed to follow the clear instructions of
their employers to disclose financial conflicts as part of their duties as
principal investigators on externally funded research grants and thereby
placed their Universities at risk of losing research funding in the future and
thwarted the efforts of NIH and FDA to uncover pervasive conflicts of
interest.
C. Three inherent forces are identified in this case for fomenting conflicts of
interest: the vertical integration of the pharmaceutical industry, the 1980
Bayh-Dole Act, and the accelerating need of the medical industry to conduct
human experiments. Which of the three suggested solutions for eliminating
conflicts of interest in the medical industry best addresses these inherent
forces?
The proposed Physicians Payments in Sunshine Act requires medical
industry companies to file quarterly reports with the Secretary of Health and
Human Services detailing payments made to physicians or their employers,
denies tax deductions for advertising, promotion or marketing expenses for
any payments not disclosed, and mandates publication of those quarterly
reports in the Federal Register to notify the public of the existence and extent
of financial interest conflicts. Hence, to the extent payments to physicians are
brought to the attention of the public, that aspect of the vertical integration of
the pharmaceutical indusfry is addressed. The proposed Physicians Payments
in Sunshine Act, however, does not address the removal of physicians and
medical scientists from participation in the transaction approval process, the
financial incentives provided to physicians and medical scientists by the
Bayh-Dole Act to commercialize medical drugs and devices, or the
accelerating need of the medical industry to conduct human experiments.
Requiring independent testing of the efficacy and safety of drugs and
medical devices by a newly created federal agency removes the physician
and medical scientist with financial links to the medical industry from the
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ultimate approval process for the dmg or medical device, and thereby does
address the impact of the fmancial contributions made by pharmaceutical
indusfries on the approval process. Independent testing, however, does not
mandate public disclosure of the financial conflicts of interest, does not
address the fmancial incentives provided by the Bayh-Dole Act, and will
likely exacerbate the need of the medical industry to conduct human
experiments.
The American Medical Association proposal provides the most
comprehensive means of disclosing financial conflicts of interest and
eliminating the benefits flowing to medical industry companies from its
direct financial support of medical conferences and continuing education
programs. All gifts, meals, travel expense reimbursement, and payments for
participating in medical company programs are prohibited. Free dmg
samples are replaced by vouchers for low income patients. Decisions on
medical institution purchases of medical devices and equipment are made
only by those without financial conflicts of interests. Financial support for
continuing education programs and meetings are ftinneled through and
disbursed by a central depository thereby eliminating the identification ofthe
medical company with the financial support for those programs. Medical
school faculty members are prohibited from participating in speaker bureaus
and accepting fees for marketing and promoting medical products. And
significant transparency is provided for accepting consulting fees and
research support. While these proposals provide far greater disclosure of
financial conflicts of interest and eliminate many practices creating such
conflicts, they do not address the financial incentives provided to physicians
and medical scientists by the Bayh-Dole Act to participate in the
commercialization of medical products and the rapidly expanding need ofthe
medical industry to conduct human experiments.
D. Discuss whether the drug company practice of "medical ghostwriting, " in
which medical companies prepare drafts of articles, editorials and research
papers, invite prominent doctors and scientists to add their names as
coauthors, and publish the work in prominent medical journals read by
practitioners who believe the publications contain independent research, is
ethical.
The dmg industry practice of medical ghostwriting is likely unethical.
To begin with, the practice of medical ghostwriting permits dmg approval
processes to proceed based on scientific evidence selected by the dmg
company to support the conclusion that the medical companies prefer, rather
than the conclusion based on the best scientific evidence. This may lead to
the approval of dmgs in new markets that improve the profitability of the
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drug companies, but may cause harm to patients in that market, as apparently
happened in the case of the "fen-phen" drug combination and the prescribed
use of antidepressants in adolescents. Likewise, practicing physicians who
read and rely on these articles and papers may prescribe drugs that may harm
their patients. From the utilitarian point of view, the practice of medical
ghostwriting may cause more negative consequences than beneficial
consequences, particularly if it triggers a loss of public confidence in the
integrity of drug companies and the drug approval process and legislative
action to reform the regulatory oversight over the drug industry.'^^
Likewise, the practice of medical ghostwriting likely misleads the
readers of the journals in which the ghostwritten papers and studies appear
about the extent to which the co-authors, generally perceived to be the
leading doctors and scientists in their fields, actually conducted the research
and formulated the scientific conclusions. From a Kantian point of view,
such deception is unethical, because it uses the readers of the ghostwritten
works as a means only to advance the interest of the pharmaceutical
companies. Further, it is unlikely that medical ghostwriting is an acceptable
universal practice that all participants in drug formulation, production,
testing, approval, and consumption would be willing to accept.'^^
Finally, viewed fî om the perspective of the Rawls' Original
Position/Veil of Ignorance Theory, it is unlikely that parties, who do not
know what position they will occupy in society or what advantages or
disadvantages they wiU possess, would be willing to permit society to
employ rules or practices that permit drug companies to engage in medical
ghostwriting. Likewise, employing Rawls' Principle of Equal Liberty, the
deceptive nature of medical ghostwriting appears to deny equal and universal
enjoyment of the most extensive basic liberties.'^'
E. Discuss whether the employment of the "celebrity medical expert " to
provide testimonials about the effectiveness of food products or medicines is
ethical.
The practice of food and drug manufacturers employing celebrity
medical experts to tout the health benefits of their products is unethical in the
absence of a disclosure that the celebrity medical expert has a confiict of
interest in promoting the products. Lisa Hark's promotions of orange juice
and Tyson Foods chicken products are misleading, if the target audience of
her message is not told she was paid as a consultant to promote those
products. Frederick Goodwin's recommendations that bipolar children could
"' Velasquez, supra note 3, at 70-72.
"' Id. at 94-97.
'"/¿/.at 114-16.
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be treated safely with mood stabilizers are misleading, if the significant
consulting fees he earned to promote those drugs are not fully disclosed. As
noted above, the use of deception does not normally produce the greatest net
amount of good for those affected by the deception; deception uses the
victim of the deception as a means only, and does not constitute an
acceptable universal practice; and deception violates Rawls' theory of
justice.
F. Should the policy of the Bayh-Dole Act to fund academic research, give
academic researchers and their institutions the right to products developed
with government money, and to permit physicians and medical scientists to
commercialize drugs and medical devices be modified or abandoned?
The Bayh-Dole Act encourages scientific research and the
commercialization of drugs and medical devises by permitting academic
researchers to license their intellectual property and develop financial ties
with the biotechnology or pharmaceutical industries. The Bayh-Dole Act has
significantly increased the participation of academic institutions in
technology transfer, enhanced their income streams, spawned new
businesses, and facilitated the movement of discoveries from the university
laboratory to the marketplace quickly and efficiently. It also enhances
employment opportunities and federal and state tax revenues, thereby
returning the benefits of scientific research full circle. Recent results of a
survey conducted by the Association of University Technology Managers,
for example, reported significant economic development was spurred in 2008
by University research and inventions: 543 new university spinoff
companies; $2.3 billion in licensing revenue for 154 institutions and their
inventors; and 4,350 licenses of inventions for new products.'^" Hence,
given the benefits generated by the Bayh-Dole act, it is doubtful whether the
incentives it provides should be modified or abandoned.
One recent example of the impact of Bayh-Dole is the disclosure by the
University of Wisconsin that Thomas A. Zdeblick, a renowned surgeon and
chairman of the department of orthopedics, earned royalty income in the
amount $19.4 million between 2003 and 2007 from Medtronic, which sells
spinal implants developed by Dr. Zdeblick. Dr. Zdeblick was the inventor of
25 U.S. patents, 7 pending U.S. patent applications, 41 foreign patents, and
20 pending foreign patent applications developed with Medtronic. In
accordance with University of Wisconsin policy. Dr. Zdeblick fully disclosed
"" Goldie Blumenstyk, University Inventions Sparked Record Number of Companies in 2008,
CHRON. OF HIGHER EDUC. (Feb. 15, 2010), http://chronicle.com/article/University-Inventions-
Sparked/64204/?sid=pm&utm_source=pm&utm_medium=en.
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his income from outside sources. Dr. Zdeblick also insists that he does not
receive any royalties on devices implanted into his patients.'^'
As Dr. Zdeblick's experience demonstrates, it is possible to neutralize
the potential impact of confiicts of interest resulting from outside income
from medical companies by fully complying with disclosure requirements,
declining royalties on products selected for the physician's patients, and
refraining from any decision making process in which the outside income
creates a confiict of interest. In short, the significant benefits of the Bayh-
Dole Act in encouraging the development and commercialization of drugs
and medical devices by supporting scientific research and ceding ownership
of the intellectual property to the academic researchers and institutions can
be maintained without triggering injurious confiicts of interest.
'•" See Paul Basken, Surgeon's Royalties Bring Heat to a Medical School with Strict Ethics
Policy, CHRON. OF HIGHER EDUC. (Feb. 27, 2009),
http://chronicle.com/daily/2009/02/12570n.htm?utm_source=at&utm_medium=en. Dr.
Zdeblick was not the only physician receiving payments from drug and medical devices
companies. "Paul A. Anderson, a professor of orthopedic surgery . . . was paid $150,000 by
Medtronic for eight days of work as a consultant; Ben K. Graf, an associate professor of
orthopedic surgery . . . collected $770,000 in royalties from the medical-device manufacturer
Smith & Nephew; and Clifford B. Tribus, an associate professor of orthopedic surgery . . . was
paid $310,000 for royalties and 15 days of work as a speaker and consultant for Stryker Spine,
another device company." Paul Basken, Severa/¿7. of Wisconsin Medical-School Professors
Accepted Large Corporate Payments, CHRON. OF HIGHER EDUC. (June 22, 2009),
http://chronicle.com/article/Several-U-of-Wisconsin-Med/47784/.
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